RECEIVED CENTRAL FAX CENTER

DEC 2 2 2006

## PATENT/Docket No. PC20702C

Appl. No. 10/801897 Filing Date: March 15, 2004

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s)

J-L Dasseux et al.

Serial Number

10/801897

Filed

March 15, 2004

For

APOLIPOPROTEIN A-I AGONISTS AND THEIR USE TO TREAT

DYSLIPIDEMIC DISORDERS

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

### COMMUNICATION

Sir:

The Assignee(s) for the above-referenced United States Patent Application has been stated incorrectly in the Pair system and on the published application as "Esperion Therapeutics, Inc." This communication is to correct the Assignee(s). The correct Assignee(s) of record are located at Reel 012153/ Frame 0214, and are as follows. Please ensure the USPTO's records and the printed patent reflect this information.

Dasseux, Jean-Louis, 7898 Huron Oak Drive, Brighton, Michigan 48116 Sekul, Renate, Wichernstr. 13, Ladenburg, Germany D-685 Buttner, Klaus, Eichendorffstr. 6, Epfenbach, Germany D-746 Cornut, Isabelle, 516 Route Du Foron, Cry, Reignier, France F-74 Metz, Gunther, Hagellachstr. 41, Heidelberg, Germany 69124 Dufourcq, Jean, 7, Ru Jacques Prevert, Pessac, France F-336

If there is a further discrepancy please contact the undersigned.

Respectfully submitted,

Martha A. Gammill, Attorney

Registration No. 31820

Pfizer Inc., Patent Department

2800 Plymouth Road Ann Arbor, MI 48105

Telephone No. (734) 622-5940 Telefax No. (734) 622-1553

FORM AMEND Rev. 5/27/03

12-22-2006

PTO/SB/21 (09-04)
Approved for use through 07/31/2006, OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Pacerwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/08 1897 TRANSMITTAL Filing Date March 15, 2004 First Named Inventor **FORM** RECEIVED J-L Dasseux Art Ifnit CENTRAL FAX CENTER 1654 Examiner Name Jeffrey E. Russel (to be used for all correspondence after initial filing) Attorney Docket Number PC20702C Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC Fee Transmittal Form Drawing(s) Appeal Communication to Board Fee Attached Licensing-related Papers of Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Repty Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Change of Correspondence Address Status Letter Other Enclosure(s) (please Identify Extension of Time Request Terminal Disclaimer below): PTOL-85 (Issue Fee Payment) - 1 Page Request for Refund Express Abandonment Request Communication - 1 Page Fee Address Indication Form - 1 Page CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Pfizer Inc Signature Printed name Martha A Gammill Date Reg. No. **CERTIFICATE OF TRANSMISSION/MAILING** I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Valerie Schipper Date Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form another suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradement Office, U.S. Department of Communication of Communications and the Chief Information Officer, U.S. Potent and ADDRESS. 85ND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

### PART B - FEE(S) TRANSMITTAL

RECEIVED CENTRAL FAX CENTER

12-22-2006

DEC 2 2 2006

Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 or Fax (571)-273-2885

INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Uso Block 1 for any change of address)

Pfizer Inc., Patent Department 2800 Plymouth Road Ann Arbor, MI 48105

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmisssom.

Certificate of Matiling or Transmission

I acreby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class small in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (371) 273-2885, on the date indicated below.

Valerie Schipper (Dopositor's name Magaire Cole Dage

			Lo	output semplane		(Squictio)	
				2 Octembre	~2006	(Date)	
APPLICATION NO.	APPLICATION NO. FILING DATE		FIRST NAMED INVENTOR		TTORNEY DOCKET NO.	CONFIRMATION NO.	
10801897 TILE OF INVENTION:	03/15/2004		Jean-Louis Dasseux		PC20702C	4097	
		iete And Their	Use To Treat Dy	01/05/2	2007 TBESHAH2 000	00034 230455	
		ingto Vita titeli	USB TO TIBELLY	01 FC:	1400.0	0 DA	
APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE	TOTAL FEESY DE	DATE DUE	
nonprovisional	NO	\$1400	\$300	\$0	\$1700	01/03/2007	
EXAMINER		ART UNIT	CLASS-SUBCLASS				
Russel, Jef	frey E	1654	514-012000	•			
Change of corresponder	nce address or indication	of "Fee Address" (37	2. For printing on the p	atent front page, list			
Change of correspondence address (or Change of Correspondence			(1) the names of up to or agents OR, alternativ	3 registered patent a rely,	tiomicys 1 Martha A	Gammil	
Address form PTO/SB/122) attached.  2 Tee Address* indication (or Tee Address* Indication form PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Contourer Number is required.			(2) the name of a single registered attorney or a 2 registered patent attor listed, no name will be	gent) and the names meys or agents. If no	ember s of up to name is 3	V. Ashbrook	
(A) NAME OF ASSIGNATION (A) NAME OF ASSIGNATION (A) NAME OF ASSEUX, F		ittner M	(B) RESIDENCE: (CITY lichtgan, Germany, Gerr	and STATE OR COL	JNTRY)	document has been filed for	
are check the appropria	to assignee category or c	stegaries (will not be pri	inted on the patent): 🚨	Individual 🚨 Corpo	station or other private gr	cup entity Government	
The following fee(s) ar	e submitted:	46	Psyment of Foc(s): (Please	e first reapply any p	reviously paid insue fee	shown above)	
Publication Fee (No small entity discount permitted)			☐ A check is enclosed. ☐ Payment by credit card. Form PTO-2038 is attached.				
			The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number 230456 (enclose an extra copy of this form).				
	s (from status indicated a	•					
	SMALL ENTITY status.		b. Applicant is no long	er claiming SMALL	ENTITY status. See 37 C	FR 1.27(g)(2).	
rest as shown by the rec	cords of the United States	Patent and Trademark	from anyone other then th Office.	e applicant; a register	ed attorney or agent; or th	assignee or other perty in	
Authorized Signature _	Marthale	. (rumil		Date /2	121/06		
Typed or printed name <u>(</u>	Martha A. Gemmil		<del></del>	Registration No.	31820		
is collection of informati application. Confidential mainting the completed a form and/or suggestion x 1450, Alexandria, Virg	on is required by 37 CFR lity is governed by 35 U. pplication form to the U is for reducing this burde pinia 22313-1450. DO N	1.311. The information S.C. 122 and 37 CFR 1. SPTO. Time will vary on n, should be sent to the OT SEND FEES OR CO	is required to obtain or re- 14. This collection is estimated in the second of the collection of the second of the collection of the colle	tain a benefit by the p nated to take 12 minu had case. Any common U.S. Patent and Trau THIS ADDRESS. SE	while which is to file (and tes to complete, includin ents on the arnount of tin lemark Office, U.S. Depa (ND TO: Commissioner)	by the USPTO to process) g gathering, preparing, and see you require to complete urtinent of Commerce, P.O. for Patents, P.O. Box 1450.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTOL-85 (Rev. 07/06) Approved for use through 04/30/2007.

OMB 0651-0033

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE